Remove Containment Remove Genotype Remove Hormones Remove Medicine
article thumbnail

Treatment of Metastatic Triple-Negative Breast Cancer

The Pharma Data

Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines. Medicines targeting these receptors therefore are not typically effective in treating TNBC. SG contains a genotoxic component and can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman.

article thumbnail

Trodelvy® for the Treatment of Metastatic Urothelial Cancer

The Pharma Data

Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor –. – New Indication Marks Second FDA Approval for Trodelvy in 2021 –. Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines.

article thumbnail

Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

“Women with triple-negative breast cancer have historically had very few effective treatment options and faced a poor prognosis,” said Aditya Bardia, MD, MPH, Director of Breast Cancer Research Program, Mass General Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and global principal investigator of the ASCENT study.

HR 52